相关实验视频
Updated: May 30, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.3K
葡萄糖素:在2型糖尿病和肥胖患者中,可能是对周围神经损害的潜在保护因素
Hao Hua1, Rui Wang1, Yu-Xian Xu1
1Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People's Hospital of Nantong City, No.666 Shengli Road, Nantong, 226001, China.
Diabetology & metabolic syndrome
|January 28, 2025
概括
在2型糖尿病 (T2D) 中,高水平的葡萄糖似乎可以保护周围神经受损,特别是在肥胖的人群中. 这表明葡萄糖可能在T2D患者的神经健康中起到有益的作用,这些患者的BMI较高.
科学领域:
- 内分泌学 在内分泌学.
- 神经学 神经学
- 代谢疾病 代谢疾病
背景情况:
- 葡萄糖水平升高是2型糖尿病 (T2D) 过度营养的一个已知的适应.
- 葡萄糖在2型糖尿病患者的周围神经功能中的特定作用需要进一步阐明,这些患者的体重指数 (BMI) 不同.
研究的目的:
- 研究T2D患者的葡萄糖水平和外周神经功能之间的关系.
- 为了在不同BMI类别 (肥胖与非肥胖) 中比较这些关联.
主要方法:
- 纳入了174名患有T2D和肥胖 (BMI ≥28 kg/m2) 的个人和480名患有T2D和非肥胖 (BMI <28 kg/m2) 的个人.
- 口服葡萄糖耐受性测试测量了葡萄糖曲线下的面积 (AUC).
- 电肌图评估了外围神经功能,包括延迟,振幅和神经传导速度 (NCV) 的复合Z分数.
主要成果:
- 在肥胖的T2D患者中,AUCgla与神经延迟,振幅和NCV有显著的相关性.
- 在T2D/肥胖组中,升高的AUCgla独立地与较低的延迟,更高的振幅和NCV有关.
- 相比之下,没有肥胖的T2D患者在AUC和神经功能参数之间没有显著的相关性.
结论:
- 增加的葡萄糖水平可能会在患有肥胖症的T2D患者中提供对外围神经损害的保护作用.
- 葡萄糖在神经健康中的作用可能在2型糖尿病中取决于BMI.
- 对糖尿病神经病变的葡萄糖向疗法的进一步研究是有必要的.
相关概念视频
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
Hormones Regulating Blood Glucose
3.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.0K
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294

